Abstract 4227: Safety of dendtritic cell and cytokine-induced killer(DC-CIK) cell based immunotherapy in patients with solid tumor: A large retrospective study in China

Abstract Background: Adoptive T cell therapy especially cytokine-induced killer cell and dendric cell treatment (DC-CIK) alone or combined with chemotherapy had significantly improved patient survival time. Although some side effects studies were briefly reported in some articles. However, systematic assessment of the adverse side effects for DC-CIK therapy, especially combined with chemotherapy has not been reported. Patients and Methods: Totally 1099 consecutive patients (2054 trail cycles) enrolled in DC-CIK treatment trials at Beijing Shijitian hospital between August 2012 and August 2018 were retrospectively reviewed, and applying Common Terminology Criteria for Adverse Events version 4.0 [CTCAE v4.0] standards to definite adverse effects (AE). Result: The 370 patients (34%)/ 815 cycles enrolled in our trail combined with chemotherapy. In total, there were 548(cases)/870(cycles) had AEs. The AE class mainly composed of Neurological 34 cycles (4%), Musculoskeletal 28 cycles (3%), Immunopathies 5 cycles(1%), Hematological 521 cycles(60%), General disorders and Administration site conditions 224 cycles(26%), Gastrointestinal 209 cycles(24%), Skin 15 cycles(2%), Metabolism and Nutrition disorders 119 cycles(14%). AE class of the Gastrointestinal (vomiting P=0.025), Nutrition disorders (anorexia P=0.016) and Hematological (anemia P<0.0001, leukopenia P<0.0001) appears in the DC-CIK treatment were mainly correlated with combined with chemotherapy. Multiple logistic regression analysis suggests that no matter whether DC-CIK was combined with chemotherapy, multi-line treatment was more prone to nausea, anorexia, fatigue, anemia and leukopenia than the first-line treatment. However, correlation analysis verified that increasing cycles of only DC-CIK treatment could reduce the incidence rate of fatigue (P=0.001), anorexia (P<0.0001) and anxiety (P=0.01). Conclusion: Most of the adverse side effects that occur during autologous DC-CIK treatment were associated with combined or previously applied chemotherapeutic treatment, which also indicates that autologous DC-CIK anti-tumor therapy was safe. At the same time, the application of DC-CIK alone treatment could also reduce the occurrence rate of some side effects. Citation Format: Shuo Wang, Jun Ren. Safety of dendtritic cell and cytokine-induced killer(DC-CIK) cell based immunotherapy in patients with solid tumor: A large retrospective study in China [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 4227.